Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer


Adult Primary Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Stage C Adult Primary Liver Cancer (BCLC) | Stage D Adult Primary Liver Cancer (BCLC)

What is the purpose of this trial?

This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to
see how well they work compared with sorafenib tosylate alone in treating patients with
liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places
in the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether giving sorafenib tosylate together with doxorubicin hydrochloride is more
effective than sorafenib tosylate alone in treating liver cancer.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
February 2010
Last Updated:
November 20, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01015833